Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and ...

Biocon Biologics presents new dermatology data from two clinical studies at EADV Congress 2024: Our Bureau, Bengaluru Wednesday, September 25, 2024, 13:40 Hrs [IST] Biocon Biologi ...

Bangalore: Biocon has announced that the U.S. Food and Drug Administration (US FDA) has concluded a surveillance inspection ...

Sensex ended the day with the gain of 256 points to 85,169 and Nifty surged 63 points to 26,004 on. Nifty Bank zoomed 133 ...

The biotechnology industry hopes the new Vigyan Dhara initiative of the Union government with a Rs. 10,000 crore outlay will result in better fund utilisation, and improve efficiency with its support ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

Piramal Pharma has set an ambitious target to double its revenue to $2 billion by FY30, while also tripling its Ebitda, ...

Piramal Pharma aims to double its revenue to $2 billion by FY30, while tripling its Ebitda, said company Chairperson Nandini ...

The global psoriatic arthritis (PsA) treatment market is poised for remarkable expansion, with an anticipated valuation of ...